Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

170.92
+2.761.64%
Volume:3.32M
Turnover:564.08M
Market Cap:44.10B
PE:-12.02
High:171.04
Open:167.66
Low:167.52
Close:168.16
52wk High:176.60
52wk Low:141.05
Shares:258.02M
Float Shares:258.02M
Volume Ratio:0.58
T/O Rate:1.29%
Dividend:2.45
Dividend Rate:1.43%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.28
PE(LYR):-12.02

Loading ...

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Sep 30

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Inflation Data Release

MT Newswires Live
·
Sep 30

LIVE Markets-TD Cowen Says AI Promises Hospitals a Margin Cure

Reuters
·
Sep 30

Pharming Group: Buy Rating Maintained and Strategy Intact Despite Surprise CEO Departure; Price Target Reaffirmed at $38

TIPRANKS
·
Sep 30

LIVE Markets-Cooler than Expected PCE Adds Some Steam to US Stock Futures

Reuters
·
Sep 30

Health Care Select Sector SPDR: Pivot points

TIPRANKS
·
Sep 30

Merck Says Experimental Skin Disease Drug Meets Main Goal in Mid-Stage Study

Reuters
·
Sep 30

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 30

Merck Says Tulisokibart Hits Primary Endpoint in Phase 2b Hidradenitis Suppurativa Trial

Reuters
·
Sep 30

Merck & Co - Study Meets Primary Endpoint Hiscr50 at Week 16 for High- and Medium-Dose Tulisokibart

THOMSON REUTERS
·
Sep 30

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2B Study in Patients with Moderate to Severe Hidradenitis Suppurativa (Hs)

THOMSON REUTERS
·
Sep 30

Merck & Co - no Serious or Opportunistic Infections Observed in Study

THOMSON REUTERS
·
Sep 30

Lilly Says Phase 3b ADtouch Trial Shows Ebglyss Beats Placebo in Hand and Foot Atopic Dermatitis Skin Clearance at Week 16

Reuters
·
Sep 30

Eli Lilly - 77% of Ebglyss Patients Reported Satisfaction with Hand Clearance at Week 16

THOMSON REUTERS
·
Sep 30

Eli Lilly - Ebglyss Monotherapy Meets Primary and Secondary Endpoints at Week 16 in Phase 3B Adtouch Study

THOMSON REUTERS
·
Sep 30

New Phase 3B Data Show Lilly's Ebglyss (Lebrikizumab-Lbkz) Delivered Significant and Rapid Improvements in Skin Clearance, Itch, Pain, and Patient Satisfaction in People with Moderate-to-Severe Hand and Foot Atopic Dermatitis

THOMSON REUTERS
·
Sep 30

Eli Lilly - Treatment-Emergent Adverse Events in 41.8% Ebglyss Patients, 39.6% Placebo, All Mild or Moderate

THOMSON REUTERS
·
Sep 30

Eli Lilly - Submits Ebglyss Adtouch Data to FDA and Plans Global Regulatory Submissions for Label Update

THOMSON REUTERS
·
Sep 30

Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded it to Sell

Dow Jones
·
Sep 30

Analysts Are Neutral on These Real Estate Stocks: National Healthcare Properties (NHP), EPR Properties (EPR)

TIPRANKS
·
Sep 30